These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 28453552)
61. Deletion of Rictor in neural progenitor cells reveals contributions of mTORC2 signaling to tuberous sclerosis complex. Carson RP; Fu C; Winzenburger P; Ess KC Hum Mol Genet; 2013 Jan; 22(1):140-52. PubMed ID: 23049074 [TBL] [Abstract][Full Text] [Related]
62. mTORC2 is required for proliferation and survival of TSC2-null cells. Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669 [TBL] [Abstract][Full Text] [Related]
63. Involvement of Rictor/mTORC2 in cardiomyocyte differentiation of mouse embryonic stem cells Zheng B; Wang J; Tang L; Tan C; Zhao Z; Xiao Y; Ge R; Zhu D Int J Biol Sci; 2017; 13(1):110-121. PubMed ID: 28123351 [TBL] [Abstract][Full Text] [Related]
64. Inhibition of 14-3-3 binding to Rictor of mTORC2 for Akt phosphorylation at Ser473 is regulated by selenoprotein W. Jeon YH; Park YH; Kwon JH; Lee JH; Kim IY Biochim Biophys Acta; 2013 Oct; 1833(10):2135-42. PubMed ID: 23680186 [TBL] [Abstract][Full Text] [Related]
69. The Bardet-Biedl syndrome-related protein CCDC28B modulates mTORC2 function and interacts with SIN1 to control cilia length independently of the mTOR complex. Cardenas-Rodriguez M; Irigoín F; Osborn DP; Gascue C; Katsanis N; Beales PL; Badano JL Hum Mol Genet; 2013 Oct; 22(20):4031-42. PubMed ID: 23727834 [TBL] [Abstract][Full Text] [Related]
70. Autoregulation of the mechanistic target of rapamycin (mTOR) complex 2 integrity is controlled by an ATP-dependent mechanism. Chen CH; Kiyan V; Zhylkibayev AA; Kazyken D; Bulgakova O; Page KE; Bersimbaev RI; Spooner E; Sarbassov DD J Biol Chem; 2013 Sep; 288(38):27019-27030. PubMed ID: 23928304 [TBL] [Abstract][Full Text] [Related]
71. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Masui K; Tanaka K; Ikegami S; Villa GR; Yang H; Yong WH; Cloughesy TF; Yamagata K; Arai N; Cavenee WK; Mischel PS Proc Natl Acad Sci U S A; 2015 Jul; 112(30):9406-11. PubMed ID: 26170313 [TBL] [Abstract][Full Text] [Related]
72. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206. Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647 [TBL] [Abstract][Full Text] [Related]
73. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Liu P; Gan W; Inuzuka H; Lazorchak AS; Gao D; Arojo O; Liu D; Wan L; Zhai B; Yu Y; Yuan M; Kim BM; Shaik S; Menon S; Gygi SP; Lee TH; Asara JM; Manning BD; Blenis J; Su B; Wei W Nat Cell Biol; 2013 Nov; 15(11):1340-50. PubMed ID: 24161930 [TBL] [Abstract][Full Text] [Related]
74. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications. Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802 [TBL] [Abstract][Full Text] [Related]
75. Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2. Luo Y; Liu L; Wu Y; Singh K; Su B; Zhang N; Liu X; Shen Y; Huang S Oncotarget; 2015 Feb; 6(6):4286-98. PubMed ID: 25738366 [TBL] [Abstract][Full Text] [Related]
76. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Pearce LR; Huang X; Boudeau J; Pawłowski R; Wullschleger S; Deak M; Ibrahim AF; Gourlay R; Magnuson MA; Alessi DR Biochem J; 2007 Aug; 405(3):513-22. PubMed ID: 17461779 [TBL] [Abstract][Full Text] [Related]
77. Role of mTOR in glioblastoma. Duzgun Z; Eroglu Z; Biray Avci C Gene; 2016 Jan; 575(2 Pt 1):187-90. PubMed ID: 26341051 [TBL] [Abstract][Full Text] [Related]
78. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. Toschi A; Lee E; Gadir N; Ohh M; Foster DA J Biol Chem; 2008 Dec; 283(50):34495-9. PubMed ID: 18945681 [TBL] [Abstract][Full Text] [Related]
79. A Preclinical Investigation of GBM-N019 as a Potential Inhibitor of Glioblastoma via Exosomal mTOR/CDK6/STAT3 Signaling. Wu ATH; Huang HS; Wen YT; Lawal B; Mokgautsi N; Huynh TT; Hsiao M; Wei L Cells; 2021 Sep; 10(9):. PubMed ID: 34572040 [TBL] [Abstract][Full Text] [Related]
80. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship. Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]